LISTEN LIVE: Supreme Court considers whether marijuana and other drug users may possess firearms

The Supreme Court is set to hear a challenge to a federal statute that bars people who regularly use marijuana or other illegal drugs from possessing firearms, with the Trump administration unusually defending the restriction and facing an alliance of the NRA and civil liberties advocates. The case — which could revive a felony gun charge against Ali Danial Hemani and rests on questions of Second Amendment scope and statutory vagueness — has broad implications for millions of state-legal cannabis users and for how other drug users may be treated under federal firearm law.

Analysis

Market structure: A Supreme Court ruling that narrows federal restrictions on firearm possession by marijuana users would be a net positive for firearm manufacturers/retailers (RGR, SWBI) and gun-accessory suppliers, while a ruling upholding the ban preserves a legal moat for background-check and compliance vendors and reduces addressable market for firearms by an estimated low-single-digit percentage of owners. Cannabis producers and MSOs (TLRY, CGC, CRON, ETF MJ) are exposed to two offsetting forces: federal reclassification (administration push) materially reduces regulatory risk and could unlock 20–40% higher institutional flows over 12–24 months, but a SCOTUS opinion that entrenches federal illegality would reintroduce banking and tax frictions.

Risk assessment: Tail risks include a narrowly worded SCOTUS reversal that creates patchwork enforcement (high-impact, low-probability) or Congressional backlash that tightens gun rules nationally; either could move sector equities ±15–30% within 3–6 months. Near-term (days) market impact should be muted; short-term (weeks–months) implied volatility in cannabis and firearms equities and MJ ETFs could jump 15–35% around the decision (likely by June–July 2026). Hidden dependencies: 280E tax exposure, access to banking/payment rails, and DOJ’s timeline for rescheduling (30–90 days) — each changes cash flow and valuation multiples.

Trade implications: Tactical plays: favor long exposure to large-cap licensed cannabis producers and the MJ ETF via 9–12 month LEAPS calls to capture rescheduling upside, while using small short positions in cyclical firearm discretionary names as a hedge. Consider buying calendar or straddle volatility on MJ (ETF) and RGR with expiries through Sep 2026 to capture event IV; size total options exposure ≤1–2% of portfolio. Rotate defensive: increase cash/IG bonds by 2–4% if ruling creates regulatory uncertainty that raises equity risk premia.

Contrarian angles: Consensus assumes rescheduling = broad upside for cannabis; that overstates near-term benefits because 280E and banking reforms require separate legislative or enforcement actions — price should not fully assume >30% revenue upside. Conversely, a SCOTUS decision invalidating the statute could provoke short-term political pushback that tightens other gun-related rules, creating a two-way risk for firearms names. Historical parallel: regulatory normalization (alcohol repeal analogy) took years — expect staggered multi-quarter realization, so scale into positions and hedge with event-driven options.

Key Decisions for Investors

• Establish a 2–3% long position in the cannabis ETF (MJ) split across 12–18 month LEAPS calls (target Sep–Dec 2026 expiries) to capture rescheduling upside; trim positions by 40% on a realized gain ≥30% or if DOJ does not publish a rescheduling rule within 90 days.
• Initiate a market-neutral pair: long TLRY (1.5% portfolio) vs short RGR (1.0% portfolio) to express asymmetric upside to cannabis rescheduling versus potential modest downside for firearms; target pair P/L stop-loss at -8% and take-profit at +25% aggregated.
• Allocate 0.5–1.0% of portfolio to event volatility trades: buy Sep–2026 ATM straddles on MJ ETF (or Sep–2026 ATM call on TLRY and put on RGR) to capture a 15–35% IV spike around the Supreme Court decision; close within 5 trading days post-decision or if IV compresses by 30%.
• Reduce/avoid small-cap MSO longs lacking positive cash flow or bank access (cut positions >2% of portfolio in names with trailing 12‑month EBITDA < $0 and debt/equity > 1.0) until 280E/tax clarity and banking access improve; redeploy proceeds into large-cap licensed producers or cash.